|Day's Range||0.1200 - 0.1200|
Last fall, the Social Security Administration—overseen by its chief trustee, Treasury Secretary Steven Mnuchin—said benefits for nearly 69 million Americans would increase 1.6% in 2020. The figure, tied to the inflation rate, meant that the average recipient would get $24 more each month, or about $1,503 annually. This figure comes from the Bureau of Labor Statistics (part of the Labor Department), which publishes what’s called the “Consumer Price Index for Urban Wage Earners and Clerical Workers” (CPI-W) on a monthly basis.
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
Pharmaceutical executives at the J.P. Morgan Healthcare conference say the industry can fixed pricing problems on its own.
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
AbbVie (ABBV) is a top pick from the healthcare sector; the stock has a 5.3% dividend yield, a low valuation, and a compelling future growth outlook thanks to a massive acquisition, suggests Ben Reynolds, editor of Sure Retirement Newsletter.
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of AbbVie Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that SKYRIZI™ met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx® in a head-to-head Phase 3 study.1 SKYRIZI showed significantly higher rates of skin clearance compared to Cosentyx, meeting the primary endpoint of superiority with at least a 90 percent improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52.1 Of patients treated with SKYRIZI, 87 percent achieved PASI 90 compared to 57 percent of Cosentyx-treated patients at 52 weeks (p<0.001).1 At week 16, SKYRIZI also met the other primary endpoint of non-inferiority to Cosentyx with 74 percent of SKYRIZI patients achieving PASI 90 compared to 66 percent of Cosentyx patients.1
Chinook Therapeutics signed a licensing deal for a lead drug that its CEO hopes to enroll in phase 3 clinical trials.
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2019 financial results on Friday, February 7, 2020 before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.